245,415 results match your criteria hepatocellular cancer

Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment.

Life Sci 2021 May 12:119612. Epub 2021 May 12.

Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden. Electronic address:

Aim Hepatocellular carcinoma (HCC) is a primary liver cancer that usually develops in a background of chronic liver disease and prolonged inflammation. A major contributor in the complex molecular pathogenesis of HCC is the highly intertwined cross-talk between the tumor and the surrounding stromal cells, such as hepatic stellate cells, endothelial cells, macrophages and other immune cells. These tumor-stroma interactions actively fuel tumor growth and modulate the hepatic microenvironment to benefit tumor invasion and disease progression. Read More

View Article and Full-Text PDF

A case of laparoscopic hepatectomy for a primary hepatic neuroendocrine tumor.

Clin J Gastroenterol 2021 May 15. Epub 2021 May 15.

Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan.

Neuroendocrine tumors (NETs) account for approximately 1-2% of all gastrointestinal tumors. In particular, primary hepatic NETs (PHNETs) are extremely rare. A 42-year-old female patient was given a diagnosis of liver tumor after a medical check-up with ultrasonography. Read More

View Article and Full-Text PDF

Current situation of viral hepatitis in Egypt.

Microbiol Immunol 2021 May 15. Epub 2021 May 15.

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.

An estimated 8-10 million people suffer from viral hepatitis in Egypt. Hepatitis A virus (HAV) and hepatitis E virus (HEV) are major causes of viral hepatitis in Egypt since ≥ 50% of the Egyptian population are already exposed to HAV infection by the age of 15 years. In addition, > 60% of the Egyptian population tested seropositive for anti-HEV in the first decade of life. Read More

View Article and Full-Text PDF

Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint.

Nat Commun 2021 May 14;12(1):2814. Epub 2021 May 14.

Division of Infection & Immunity, Institute of Immunity & Transplantation, University College London, London, UK.

Determining divergent metabolic requirements of T cells, and the viruses and tumours they fail to combat, could provide new therapeutic checkpoints. Inhibition of acyl-CoA:cholesterol acyltransferase (ACAT) has direct anti-carcinogenic activity. Here, we show that ACAT inhibition has antiviral activity against hepatitis B (HBV), as well as boosting protective anti-HBV and anti-hepatocellular carcinoma (HCC) T cells. Read More

View Article and Full-Text PDF

Therapeutic potential of targeting membrane-spanning proteoglycan SDC4 in hepatocellular carcinoma.

Cell Death Dis 2021 May 14;12(5):492. Epub 2021 May 14.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Syndecan-4 (SDC4) functions as a major endogenous membrane-associated receptor and widely regulates cytoskeleton, cell adhesion, and cell migration in human tumorigenesis and development, which represents a charming anti-cancer therapeutic target. Here, SDC4 was identified as a direct cellular target of small-molecule bufalin with anti-hepatocellular carcinoma (HCC) activity. Mechanism studies revealed that bufalin directly bond to SDC4 and selectively increased SDC4 interaction with substrate protein DEAD-box helicase 23 (DDX23) to induce HCC genomic instability. Read More

View Article and Full-Text PDF

H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.

Med Sci Monit 2021 May 15;27:e930215. Epub 2021 May 15.

Department of Endoscopy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China (mainland).

BACKGROUND Several risk factors contribute to the inflammation promoting hepatocellular carcinoma (HCC) development, but the underlying mechanisms are unknown. Human endogenous retrovirus H long terminal repeat-associating 2 (HHLA2), a B7 family member, is highly expressed in various malignant tumor tissues and is related to tumor progression and metastasis. MATERIAL AND METHODS Bioinformatics analysis was used to analyze the gene expression chip GSE33006 of HCC tissue in the GEO database, draw a heat map of differentially expressed genes, and analyze the GO pathway of gene function annotation. Read More

View Article and Full-Text PDF


Mol Pharmacol 2021 May 14. Epub 2021 May 14.

Centre de Recherche des Cordeliers, INSERM UMRS1138, France

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is one of the leading causes of cancer-related deaths worldwide. The multi-target inhibitor sorafenib is a first-line treatment for patients with advanced unresectable HCC. Recent clinical studies have evidenced that patients treated with sorafenib together with the anti-diabetic drug metformin have a survival disadvantage compared to patients receiving sorafenib only. Read More

View Article and Full-Text PDF

Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis.

BMC Gastroenterol 2021 May 14;21(1):220. Epub 2021 May 14.

Division of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 807, Taiwan, ROC.

Background: The benefits of surgical resection (SR) for various Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma (HCC) remain unclear. We investigated the risk factors of overall survival (OS) and survival benefits of SR over nonsurgical treatments in patients with HCC of various BCLC stages.

Methods: Overall, 2316 HCC patients were included, and their clinicopathological data and OS were recorded. Read More

View Article and Full-Text PDF

Lysionotin Induces Apoptosis of Hepatocellular Carcinoma Cells via Caspase-3 Mediated Mitochondrial Pathway.

Chem Biol Interact 2021 May 11:109500. Epub 2021 May 11.

Department of Translational Medicine Research, First Hospital, Jilin University, Changchun, Jilin, 130061, China. Electronic address:

As the sixth most prevalent cancer, liver cancer has been reported as the second cause of cancer-induced deaths globally. Lysionotin, a flavonoid compound widely distributed in Lysionotus pauciflorus Maxim, has attracted considerable attention due to its multiple biological activities. The present study analyzes the anti-liver cancer effects of lysionotin in cell and mouse models. Read More

View Article and Full-Text PDF

Mechanisms and disease consequences of nonalcoholic fatty liver disease.

Cell 2021 May;184(10):2537-2564

Departments of Internal Medicine and Cellular & Molecular Physiology, Yale Diabetes Research Center, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address:

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver injury that can lead to cirrhosis and hepatocellular carcinoma. Here we provide an in-depth discussion of the underlying pathogenetic mechanisms that lead to progressive liver injury, including the metabolic origins of NAFLD, the effect of NAFLD on hepatic glucose and lipid metabolism, bile acid toxicity, macrophage dysfunction, and hepatic stellate cell activation, and consider the role of genetic, epigenetic, and environmental factors that promote fibrosis progression and risk of hepatocellular carcinoma in NASH. Read More

View Article and Full-Text PDF

Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion.

FEBS Open Bio 2021 May 14. Epub 2021 May 14.

Department of Immunology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.

This study aimed to evaluate the prognostic value and biological function of small ubiquitin-like modifier 2 (SUMO2) in hepatocellular carcinoma (HCC). SUMO2 expression in HCC tissues was markedly higher than that in normal liver tissues, and patients with high SUMO2 expression had significantly shorter median overall survival than those with low SUMO2 expression. Furthermore, SUMO2 expression was closely correlated with lymph node metastasis and vascular invasion and was a predictor of poor prognosis. Read More

View Article and Full-Text PDF

Identification and validation of ADME genes as prognosis and therapy markers for hepatocellular carcinoma patients.

Biosci Rep 2021 May 14. Epub 2021 May 14.

Xuanwu Hospital of Capital Medical University, Beijing, China.

Purpose: ADME genes are genes involved in drug absorption, distribution, metabolism, and excretion (ADME). Previous studies report that expression levels of ADME-related genes correlate with prognosis of hepatocellular carcinoma (HCC) patients. However, the role of ADME gene expression on HCC prognosis has not been fully explored. Read More

View Article and Full-Text PDF

LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.

Korean J Radiol 2021 May 4. Epub 2021 May 4.

Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Objective: To assess the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 treatment response algorithm (TRA) for the evaluation of hepatocellular carcinoma (HCC) treated with transarterial radioembolization.

Materials And Methods: This retrospective study included patients who underwent transarterial radioembolization for HCC followed by hepatic surgery between January 2011 and December 2019. The resected lesions were determined to have either complete (100%) or incomplete (< 100%) necrosis based on histopathology. Read More

View Article and Full-Text PDF

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.

Biomed Res Int 2021 16;2021:5556306. Epub 2021 Apr 16.

Medical School, Anhui University of Science & Technology, Huainan 232001, China.

Acquired resistance of hepatocellular carcinoma (HCC) to sorafenib (SFB) is the main reason for the failure of SFB treatment of the cancer. Abnormal activation of the PI3K/AKT/mTOR pathway is important in the acquired resistance of SFB. Therefore, we investigated whether BEZ235 (BEZ) could reverse acquired sorafenib resistance by targeting the PI3K/mTOR pathway. Read More

View Article and Full-Text PDF

Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis.

Ann Transl Med 2021 Apr;9(8):675

Department of Minimally Invasive Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangzhou, China.

Background: Circular RNAs (circRNAs) are a class of non-coding RNAs that have been demonstrated to play important roles in tumorigenesis. However, how circRNAs regulate the progression of hepatocellular cancer (HCC) remains unclear.

Methods: In the present study, circRNA microarray analyses were performed with HCC tissues to identify circRNAs that are differentially expressed. Read More

View Article and Full-Text PDF

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.

Ann Transl Med 2021 Apr;9(8):652

Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.

Background: This study aimed to evaluate safety and efficacy of programmed death-1 (PD-1) inhibitor sintilimab plus tyrosine kinase inhibitors (TKI) in a real-word cohort of patients with unresectable hepatocellular carcinoma (uHCC).

Methods: A total of 60 patients treated with sintilimab plus TKI between February 2019 and December 2019 were enrolled. Radiological response was recorded by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline and every 6-12 weeks after treatment initiation. Read More

View Article and Full-Text PDF

Lycopene alleviates hepatic ischemia reperfusion injury via the Nrf2/HO-1 pathway mediated NLRP3 inflammasome inhibition in Kupffer cells.

Ann Transl Med 2021 Apr;9(8):631

School of Medicine, Southeast University, Nanjing, China.

Background: Lycopene is a naturally occurring carotenoid found in many fruits and vegetables, which has antioxidant effects. Although lycopene's protective effect has been observed on ischemia reperfusion (IR) injury in different organs, the effect of lycopene on Kupffer cells (KCs) has not been clearly elucidated in IR-induced acute hepatic inflammatory injury.

Methods: Mice were administered with either olive oil (10 mL/kg body weight) as the control or lycopene (20 mg/kg body weight) by gavage for 2 weeks before undergoing hepatic IR injury. Read More

View Article and Full-Text PDF

Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.

PeerJ 2021 3;9:e11342. Epub 2021 May 3.

Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, China.

Background: Hepatocellular carcinoma (HCC) is one of the deadliest tumors. The majority of HCC is detected in the late stage, and the clinical results for HCC patients are poor. There is an urgent need to discover early diagnostic biomarkers and potential therapeutic targets for HCC. Read More

View Article and Full-Text PDF

Identification of a five-gene signature in association with overall survival for hepatocellular carcinoma.

PeerJ 2021 28;9:e11273. Epub 2021 Apr 28.

Department of Histology and Embryology, Binzhou Medical University, Yantai, Shandong, China.

Background: Hepatocellular carcinoma (HCC) is considered to be a malignant tumor with a high incidence and a high mortality. Accurate prognostic models are urgently needed. The present study was aimed at screening the critical genes for prognosis of HCC. Read More

View Article and Full-Text PDF

miR-660 promotes liver cancer cell proliferation by targeting PPP2R2A.

Exp Ther Med 2021 Jul 25;22(1):683. Epub 2021 Apr 25.

Department of Biliary-Hepatic Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550025, P.R China.

Liver cancer (LC) is the leading cause for tumor-related death worldwide, and microRNAs (miRs) have been demonstrated to regulate the progression of LC. In the current study, the function of miR-660 in LC cells was investigated, and the results indicated that miR-660 was highly expressed in LC tissues and cells. This increased expression promoted LC cell proliferation and increased the percentage of S phase cells, while miR-660 knockdown inhibited cell proliferation and increased the percentage of G/G phase cells. Read More

View Article and Full-Text PDF

Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.

Sci Rep 2021 May 13;11(1):10252. Epub 2021 May 13.

Department of Neuroscience and Pharmacology, University of Iowa, 2-570 Bowen Science Building, 51 Newton Road, Iowa City, IA, 52242, USA.

Pancreatic neuroendocrine neoplasms (pNENs) are slow growing cancers of increasing incidence that lack effective treatments once they become metastatic. Unfortunately, nearly half of pNEN patients present with metastatic liver tumors at diagnosis and current therapies fail to improve overall survival. Pre-clinical models of pNEN metastasis are needed to advance our understanding of the mechanisms driving the metastatic process and for the development of novel, targeted therapeutic interventions. Read More

View Article and Full-Text PDF

CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.

Mol Cancer 2021 May 13;20(1):75. Epub 2021 May 13.

Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 YiXue Yuan Road, Shanghai, 200032, China.

Background: Cirrhosis is a recognized risk factor for developing hepatocellular carcinoma (HCC). Few studies have reported the expression profile of circRNAs in HCC samples compared to paratumour dysplastic nodule (DN) samples.

Methods: The Arraystar Human circRNA Array combined with laser capture microdissection (LCM) was used to analyse the expression profile of circRNAs in HCC samples compared to paratumour DN samples. Read More

View Article and Full-Text PDF

Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver.

Semin Liver Dis 2021 May 6. Epub 2021 May 6.

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Current treatments for hepatitis B virus (HBV) using nucleos(t)ide analogs cannot eliminate the risk of hepatocellular carcinoma (HCC) development. As HBV-associated HCC can develop even in the absence of liver cirrhosis, HBV is regarded to possess direct oncogenic potential. HBV regulatory protein X (HBx) has been identified as a primary mediator of HBV-mediated hepatocarcinogenesis. Read More

View Article and Full-Text PDF

Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.

Phytomedicine 2021 Apr 18;87:153575. Epub 2021 Apr 18.

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Electronic address:

Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with limited treatment options. Conventional antitumor therapy combined with traditional Chinese medicine (TCM) to limit tumor progression has gradually become the focus of complementary and alternative therapies for HCC treatment. The Fuzheng Jiedu Xiaoji formulation (FZJDXJ) alleviates the clinical symptoms of patients and inhibits tumor progression, but its curative effect still requires extensive clinical research and mechanistic analysis. Read More

View Article and Full-Text PDF

A novel classification of portal venous tumor invasion to predict residual tumor status after surgery in patients with pancreatic neuroendocrine neoplasms.

J Cancer Res Clin Oncol 2021 May 13. Epub 2021 May 13.

Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.

Purpose: To elucidate whether portal venous tumor invasion (PVTI) is a prognostic factor for patients with pancreatic neuroendocrine neoplasms (Pan-NENs).

Methods: From 2002 to 2019, 240 patients with Pan-NEN were included to examine prognostic factors. PVTI based on computed tomography (CT) images are classified into four types: no PVTI (Vp0/1), PVTI not invading the superior mesenteric vein (Vp2), PVTI invading the superior mesenteric vein or portal vein (Vp3), and PVTI invading the portal bifurcation (Vp4). Read More

View Article and Full-Text PDF

LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.

Mol Med Rep 2021 Jul 13;24(1). Epub 2021 May 13.

Medical School, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China.

Liver cancer remains one of the leading causes of cancer deaths worldwide. The therapeutic effect of oxaliplatin on liver cancer is often limited by acquired resistance of the cancer cells. Abnormal activation of the PI3K/AKT pathway plays an important role in the acquired resistance of oxaliplatin. Read More

View Article and Full-Text PDF

Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.

Hepatol Res 2021 May 13. Epub 2021 May 13.

Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.

We herein report two cases of locally advanced unresectable hepatocellular carcinoma (u-HCC) that were resected after achieving a radiological complete response to initially administered lenvatinib followed by transcatheter arterial chemoembolization (LEN-TACE sequential therapy). A 78-year-old woman and an 80-year-old man with HCC of Barcelona Clinic Liver Cancer classification stage C were treated for 15 and 14 months with lenvatinib, respectively. Both patients were subsequently treated with TACE, resulting in complete remission on imaging. Read More

View Article and Full-Text PDF

TFB2M activates aerobic glycolysis in hepatocellular carcinoma cells through the NAD /SIRT3/HIF-1α signaling.

J Gastroenterol Hepatol 2021 May 12. Epub 2021 May 12.

Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Background: Increased aerobic glycolysis has been well-known as a hallmark of cancer, which is closely related to mitochondrial dysfunction. TFB2M (mitochondrial transcription factor B2) is a core mitochondrial transcription factor, which has been shown by us to play an oncogenic role in hepatocellular carcinoma (HCC). However, whether TFB2M contributes to the aerobic glycolysis in HCC cells remains unexplored. Read More

View Article and Full-Text PDF

Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.

Dig Dis Sci 2021 May 12. Epub 2021 May 12.

Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, 430071, People's Republic of China.

Background: With the rise of liquid biopsy in oncology, circulating miRNAs have become one of the most promising noninvasive biomarkers for early detection of hepatocellular carcinoma (HCC). However, a reliable HCC-related circulating miRNA panel and corresponding diagnostic model remain to be explored.

Methods: Five large public datasets related to intact miRNA profiles in the serum or tumors of HCC patients were included and divided into training cohorts (GSE113740 and TCGA-LIHC) and validation cohorts (GSE112264, GSE113486 and GSE106817). Read More

View Article and Full-Text PDF

Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Purinergic Signal 2021 May 12. Epub 2021 May 12.

Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Querétaro, México.

Cancer comprises a collection of diseases that occur in almost any tissue and it is characterized by an abnormal and uncontrolled cell growth that results in tumor formation and propagation to other tissues, causing tissue and organ malfunction and death. Despite the undeniable improvement in cancer diagnostics and therapy, there is an urgent need for new therapeutic and preventive strategies with improved efficacy and fewer side effects. In this context, purinergic signaling emerges as an interesting candidate as a cancer biomarker or therapeutic target. Read More

View Article and Full-Text PDF